Data from switching studies will bolster another important facet of the biosimilars marketplace: patient and prescriber confidence. In a marketplace in which patients move from one formulary to another, from one year to the next in their journey with chronic illnesses, it will be helpful to know that interchangeable biosimilars offer equal safety and efficacy after multiple switches.
This spring, the FDA released the final guidance to drug makers for the approval process for interchangeable biosimilars. This marks an important moment in the process of lowering prices of breakthrough biologic drugs and improving patients’ access to them. It also allows for an opportunity to review the biosimilars marketplace and next steps.
First, a brief review of where we are in the US: As a practicing rheumatologist, I can prescribe only 1 kind of biosimilar to my patients: infliximab. In my experience of using biosimilar infliximab in patients who agree to switch from the bio-originator (Remicade) and those who start it from scratch (so called “biologic naïve” patients), the biosimilar has been therapeutically equivalent, which is to say equally safe and effective as expected with the bio-originator. This is not surprising to me or to my patients, who have heard my counsel about the rigorous FDA approval process and about published data like the 2017 NOR-SWITCH study.
For many people receiving biosimilars—and their fellow beneficiaries of public and commercial insurance—total drug costs are falling. Remicade costs about 30% less than it used to (after decades of price increases) and biosimilar infliximabs cost more than 15% less than Remicade. But biosimilar uptake and price reductions have been modest, and several changes could fix that.
The first thing that could improve the biologics marketplace is competition. Only 2 biosimilars are available for rheumatologic diseases, but 6 other biosimilars (3 adalimumabs, 2 etanercepts, and 1 infliximab) are FDA-approved but not marketed due to legal disputes and drug-maker decisions. When they do become available, prices should drop again.
Furthermore, now that the FDA has given drug makers a pathway to seek an interchangeability designation, it is hoped that clinical studies will produce rigorous switching data and possibly increase the number of biosimilars. The data will arise from studies in which patients switch 3 times, alternating from the bio-originator to the biosimilar, back to the bio-originator, and finally to the biosimilar.
Data from switching studies will bolster another important facet of the biosimilars marketplace: patient and prescriber confidence. In a marketplace in which patients move from one formulary to another and from one year to the next in their journey with chronic illnesses, it will be helpful to know that interchangeable biosimilars offer equal safety and efficacy after multiple switches.
Finally, in addition to improved competition and confidence in biosimilars, incentives could be improved. Patients should share in the savings of biosimilars by being exempt from copays. Reimbursement systems should also account for the extra work and time required of prescribers to counsel their patients about biosimilars. And, as has been pointed out previously, the rebates in the US drug distribution system—which can incentivize higher prices—must be reformed so that pharmacy benefit managers and other organizations support prescribers and patients who choose biosimilars instead of blocking them.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
FDA's Expanded Access: From Laetrile to Right to Try, Ethical Debates Over Early Drug Access
April 28th 2025Christopher T. Robertson, JD, PhD, reviewed the history and ethical landscape of providing access to drugs before FDA approval, highlighting the crucial role of clinical trials and ethical safeguards at the 2025 Festival of Biologics USA.